



Transparency notification

Brussels (Belgium), 20 December 2016 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 15 December 2016, from BlackRock, Inc. (having its registered offices at 55 East 52nd Street, New York, NY, 10055, U.S.A.).

BlackRock, Inc. has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV had decreased and has crossed downward the 3% minimum threshold.

On 13 December 2016, BlackRock, Inc. (taking into account the holding of its affiliates) owned 5 742 848 UCB shares with voting rights (versus 5 840 557 UCB shares in its previous notification dated 12 December 2016), representing 2.95% of the total number of shares issued by the company (194 505 658) (versus 3.00% in the notification dated 12 December 2016).

2. Content of the notification

The transparency notification dated 15 December 2016 included the following information:

- Reason for the notification: Acquisition or disposal of voting securities or voting rights
- **Notification by**: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:



Name	Address (for legal entities)					
BlackRock, Inc	55 East 52nd Street, New York, NY, 10055, U.S.A.					
BlackRock (Netherlands) B.V.	Rembrandt Tower, 17th floor, Amstelplein, Amsterdam, Netherlands					
BlackRock (Singapore) Limited	20 Anson Road #18-01, Singapore, 79912, Singapore					
BlackRock Advisors (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.					
BlackRock Advisors, LLC	100 Bellevue Parkway, Wilmington, DE, 19809, U.S.A.					
BlackRock Asset Management Canada Limited	161 Bay Street, Suite 2500, Toronto, Ontario, M5J 2S1, Canada					
BlackRock Asset Management Deutschland AG	Max-Joseph-Straße 6, Munich, 80333, Germany					
BlackRock Asset Management North Asia Limited	15/F, 16/F, 17/F Citibank Tower & 17/F ICBC Tower, 3 Garden Road, Central, Hong Kong					
BlackRock Financial Management, Inc.	55 East 52nd Street, New York, NY, 10055, U.S.A.					
BlackRock Fund Advisors	400 Howard Street, San Francisco, CA, 94105, U.S.A.					
BlackRock Institutional Trust Company, National Association	400 Howard Street, San Francisco, CA, 94105, U.S.A.					
BlackRock International Limited	Exchange Place One, 1 Semple Street, Edinburgh, EH3 8BL, U.K.					
BlackRock Investment Management (Australia) Limited	Level 37, Chifley Tower, 2 Chifley Square, Sydney NSW 2000 Australia					
BlackRock Investment Management (UK) Limited	12 Throgmorton Avenue, London, EC2N 2DL, U.K.					
BlackRock Investment Management, LLC	1 University Square Drive, Princeton, NJ, 8540, U.S.A.					
BlackRock Japan Co., Ltd.	1-8-3 Marunouchi Chiyoda-ku, Trust Tower Main, Tokyo, 100-8217, Japan					

Date on which the threshold is crossed: 13 December 2016.

• Threshold crossed (in %): 3%.

• **Denominator**: 194 505 658.

Notified details:





A) Voting rights	Previous notification			After the transaction					
	# of voting rights	# of voting rights # of voting			ng righ	ts	ng rights		
Holders of voting rights			Linked to	securities		nked to the ecurities	Linked to securities	Not linked to the securities	
BlackRock, Inc 0			0				0,00%		
BlackRock (Netherlands) B.V. 19.816			19.816				0,01%		
BlackRock (Singapore) Limited 7.217			7.217				0,00%		
BlackRock Advisors (UK) Limited 925.459			829.231				0,43%		
BlackRock Advisors, LLC 51.925			51.925				0,03%		
BlackRock Asset Management Canada Limited			61.015			0,03%			
BlackRock Asset Management Deutschland AG	222.966	222.966		23.206			0,11%		
BlackRock Asset Management Nort Asia Limited	th 644	644		44			0,00%		
BlackRock Financial Management, Inc.	81.434	81.434		1.434			0,04%		
BlackRock Fund Advisors	1.779.288	1.779.288		72.924			0,91%		
BlackRock Institutional Trust Company, National Association	2.066.009		2.05	59.707			1,06%		
BlackRock International Limited	14.159	14.159		2.706			0,01%		
BlackRock Investment Management (Australia) Limited	t 41.549		41	.549			0,02%		
BlackRock Investment Management (UK) Limited	164.329		16	62.867			0,08%		
BlackRock Investment Management LLC	t, 237.515	237.515		37.680			0,12%		
BlackRock Japan Co., Ltd.	167.232	167.232		180.927			0,09%		
Subtotal	5.840.557	5.840.557		5.742.848			2,95%		
TOTAL			5.742.848			0	2,95%	0,00%	
B) Equivalent financial instruments				After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expira	ation date	Exercise po		# of voting rig that may be acquired if the instrument in exercised	ne % of voting righ	ts Settlement	
BlackRock Advisors (UK) Limited	Securities Lent					133.099	0,07%	physical	
	Securities Lent					1.118	0,00%	physical	
Company, National Association	Securities Lent					9.606	0,00%	physical	
BlackRock Institutional Trust Company, National Association	Contract for Difference					65.447	0,03%	cash	
	Contract for Difference					10.772	0,01%	cash	
BlackRock Investment Management (UK) Limited	Contract for Difference					158.896	0,08%	cash	
·	TOTAL					378.938	0,19%	_	
	TOTAL (A & B)					# of voting rig	hts % of voting righ	ts	
L	<u> </u>						1	-1	

CALCULATE

6.121.786

3,15%



• Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in the PDF which is attached to the notification.

Additional information:

The disclosure obligation arose due to voting rights for BlackRock, Inc. going below 3%.

3. Further information

This press release and the detailed transparency notification is available on UCB SA/NV's website via the following <u>link</u>.

An updated overview of the UCB SA/NV large shareholdings will be included in the corporate governance charter of UCB SA/NV, which is available on its website via the following link.

Investor Relations

Antje Witte, Investor Relations, UCB T +32 2 559 94 14, antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T +32 2 559 95 88, isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of €3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

